Predictors of early abstinence in smokers with schizophrenia

Journal of Clinical Psychiatry

Volumn 69, Issue 11, 2008, Pages 1743-1750

  Culhane, Melissa A ^a   Schoenfeld, David A ^a   Barr, Ruth S ^a   Cather, Corinne ^a   Deckersbach, Thilo ^a   Freudenreich, Oliver ^a   Goff, Donald C ^a   Rigotti, Nancy A ^a   Evins, A Eden ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Freedom Trail Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; NICOTINE GUM; NICOTINE PATCH; PLACEBO;

ABSTINENCE; ARTICLE; ATTENTION; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; CONTINUOUS PERFORMANCE TEST AX; HUMAN; MENTAL TEST; NICOTINE REPLACEMENT THERAPY; PREDICTION; PRIORITY JOURNAL; RESPONSE TIME; SCHIZOPHRENIA; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT OUTCOME;

EID: 57349128802     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n1109     Document Type: Article

References (83)

1. US Centers for Disease Control and Prevention. Tobacco use among adults - United States, 2005. Morbidity and Mortality Weekly Report 2006 Oct 27;55(42):1145-1148
2. de Leon J, Dadvand M, Canuso C, et al. Schizophrenia and smoking: an epidemiological survey in a state hospital. Am J Psychiatry 1995;152:453-455
3. de Leon J, Tracy J, McCann E, et al. Schizophrenia and tobacco smoking: a replication study in another US psychiatric hospital. Schizophr Res 2002;56:55-65
4. Kelly C, Sharkey V, Morrison G, et al. Nithsdale Schizophrenia Surveys, 20: cognitive function in a catchment-area-based population of patients with schizophrenia. Br J Psychiatry 2000;177:348-353
5. Olincy A, Young DA, Freedman R. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol Psychiatry 1997;42:1-5
6. Williams JM, Ziedonis DM, Abanyie F, et al. Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaffective disorder is not a metabolic effect. Schizophr Res 2005;79:323-335
7. de Leon J, Diaz FJ, Rogers T, et al. Initiation of daily smoking and nicotine dependence in schizophrenia and mood disorders. Schizophr Res 2002;56:47-54
8. Diwan A, Castine M, Pomerleau CS, et al. Differential prevalence of cigarette smoking in patients with schizophrenic vs mood disorders. Schizophr Res 1998;33:113-118
9. Hannerz H, Borga P, Borritz M. Life expectancies for people with psychiatric diagnoses. Public Health 2001;115:328-337
10. Brown S. Excess mortality of schizophrenia: a meta-analysis. Br J Psychiatry 1997;171:502-508
11. Joukamaa M, Heliovaara M, Knekt P, et al. Mental disorders and cause-specific mortality. Br J Psychiatry 2001;179:498-502
12. Narrow WE, Rae DS, Robins LN, et al. Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys' estimates. Arch Gen Psychiatry 2002;59:115-123
13. Addington J, el-Guebaly N, Addington D, et al. Readiness to stop smoking in schizophrenia. Can J Psychiatry 1997;42:49-52
14. Evins AE, Cather C, Rigotti NA, et al. Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction. J Clin Psychiatry 2004 Mar;65(3):307-311
15. Lader D, Meltzer H. Smoking Related Behaviour and Attitudes. London, England: Office for National Statistics, Department of Health; 2001
16. Ziedonis DM, George TP. Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull 1997;23:247-254
17. Dalack GW, Becks L, Hill E, et al. Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia. Neuropsychopharmacology 1999;21:195-202
18. Evins AE, Cather C, Deckersbach T, et al. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol 2005;25:218-225
19. Baker A, Richmond R, Haile M, et al. A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder. Am J Psychiatry 2006;163:1934-1942
20. George TP, Vessicchio JC, Sacco KA, et al. A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biol Psychiatry 2008;63:1092-1096
21. Aubin HJ. Tolerability and safety of sustained-release bupropion in the management of smoking cessation. Drugs 2002;62(suppl 2):45-52
22. Chandola T, Head J, Bartley M. Socio-demographic predictors of quitting smoking: how important are household factors? Addiction 2004;99:770-777
23. Ferguson JA, Patten CA, Schroeder DR, et al. Predictors of 6-month tobacco abstinence among 1224 cigarette smokers treated for nicotine dependence. Addict Behav 2003;28:1203-1218
24. Hurt RD, Wolter TD, Rigotti N, et al. Bupropion for pharmacologic relapse prevention to smoking: predictors of outcome. Addict Behav 2002;27:493-507
25. Breese CR, Lee MJ, Adams CE, et al. Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 2000;23:351-364
26. Durany N, Zochling R, Boissl KW, et al. Human post-mortem striatal alpha4beta2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome. Neurosci Lett 2000;287:109-112
27. Freedman R, Hall M, Adler LE, et al. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 1995;38:22-33
28. Cornblatt BA, Keilp JG. Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophr Bull 1994;20:31-46
29. Liu SK, Chiu CH, Chang CJ, et al. Deficits in sustained attention in schizophrenia and affective disorders: stable versus state-dependent markers. Am J Psychiatry 2002;159:975-982
30. Sullivan EV, Shear PK, Zipursky RB, et al. A deficit profile of executive, memory, and motor functions in schizophrenia. Biol Psychiatry 1994;36:641-653
31. Wiedl KH, Wienobst J, Schottke HH, et al. Attentional characteristics of schizophrenia patients differing in learning proficiency on the Wisconsin Card Sorting Test. Schizophr Bull 2001;27:687-695
32. Depatie L, O'Driscoll GA, Holahan AL, et al. Nicotine and behavioral markers of risk for schizophrenia: a double-blind, placebo-controlled, cross-over study. Neuropsychopharmacology 2002;27:1056-1070
33. Harris JG, Kongs S, Allensworth D, et al. Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology 2004;29:1378-1385
34. Levin ED, Wilson W, Rose JE, et al. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 1996;15:429-436
35. Myers CS, Robles O, Kakoyannis AN, et al. Nicotine improves delayed recognition in schizophrenic patients. Psychopharmacology (Berl) 2004 Jul;174(3):334-340
36. Smith RC, Singh A, Infante M, et al. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology 2002;27:479-497
37. George TP, Vessicchio JC, Termine A, et al. Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology 2002;26:75-85
38. US Centers for Disease Control and Prevention. Cigarette smoking among adults-United States, 2000. Morbidity and Mortality Weekly Report 2002 Jul 26;51(29):642-645
39. Hughes J. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986;143:993-997
40. Meltzer H, Gill B, Pettigrew M. Economic Activity and Social Functioning of Adults With Psychiatric Disorders. Rep. 3. London, England: HMSO; 1996
41. Tidey JW, Rohsenow DJ, Kaplan GB, et al. Cigarette smoking topography in smokers with schizophrenia and matched non-psychiatric controls. Drug Alcohol Depend 2005;80:259-265
42. Evins AE, Cather C, Culhane MA, et al. A 12-week double-blind, placebo-controlled study of bupropion SR added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol 2007;27:380-386
43. Evins AE, Mays VK, Rigotti NA, et al. A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine Tob Res 2001;3:397-403
44. Dolan SL, Sacco KA, Termine A, et al. Neuropsychological deficits are associated with smoking cessation treatment failure in patients with schizophrenia. Schizophr Res 2004;70:263-275
45. Hosmer D Jr, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley and Sons; 1989
46. Godtfredsen NS, Prescott E, Osler M, et al. Predictors of smoking reduction and cessation in a cohort of Danish moderate and heavy smokers. Prev Med 2001;33:46-52
47. Gatto GJ, Bohme GA, Caldwell WS, et al. TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects. CNS Drug Rev 2004;10(2):147-166
48. Lawrence NS, Ross TJ, Stein EA. Cognitive mechanisms of nicotine on visual attention. Neuron 2002;36:539-548
49. Levin ED, Rezvani AH. Development of nicotinic drug therapy for cognitive disorders. Eur J Pharmacol 2000;393:141-146
50. McClernon FJ, Gilbert DG, Radtke R. Effects of transdermal nicotine on lateralized identification and memory interference. Hum Psychopharmacol 2003;18:339-343
51. McGaughy J, Sarter M. Effects of ovariectomy, 192 IgG-saporin-induced cortical cholinergic deafferentation, and administration of estradiol on sustained attention performance in rats. Behav Neurosci 1999;113:1216-1232
52. Puma C, Deschaux O, Molimard R, et al. Nicotine improves memory in an object recognition task in rats. Eur Neuropsychopharmacol 1999;9:323-327
53. Rezvani AH, Bushnell PJ, Levin ED. Effects of nicotine and mecamylamine on choice accuracy in an operant visual signal detection task in female rats. Psychopharmacology (Berl) 2002;164:369-375
54. Rezvani AH, Levin ED. Nicotine-antipsychotic drug interactions and attentional performance in female rats. Eur J Pharmacol 2004;486:175-182
55. Levin ED, Torry D. Acute and chronic nicotine effects on working memory in aged rats. Psychopharmacology (Berl) 1996;123:88-97
56. Levin ED. Nicotinic receptor subtypes and cognitive function. J Neurobiol 2002;53(4):633-640
57. Levin ED, Conners CK, Silva D, et al. Effects of chronic nicotine and methylphenidate in adults with attention deficit/hyperactivity disorder. Exp Clin Psychopharmacol 2001;9:83-90
58. Poltavski DV, Petros T. Effects of transdermal nicotine on attention in adult non-smokers with and without attentional deficits. Physiol Behav 2006;87:614-624
59. White HK, Levin ED. Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease. Psychopharmacology 1999;143:158-165
60. White HK, Levin ED. Chronic transdermal nicotine patch treatment effects on cognitive performance in age-associated memory impairment. Psychopharmacology (Berl) 2004;171:465-471
61. Evins AE, Deckersbach T, Cather C, et al. Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia. J Clin Psychiatry 2005 Sep;66(9):1184-1190
62. Jacobsen LK, Krystal JH, Mencl WE, et al. Effects of smoking and smoking abstinence on cognition in adolescent tobacco smokers. Biol Psychiatry 2005;57:56-66
63. Jacobsen LK, Slotkin TA, Westerveld M, et al. Visuospatial memory deficits emerging during nicotine withdrawal in adolescents with prenatal exposure to active maternal smoking. Neuropsychopharmacology 2006;31:1550-1561
64. Sacco KA, Termine A, Seyal A, et al. Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch Gen Psychiatry 2005;62:649-659
65. Xu J, Mendrek A, Cohen MS, et al. Brain activity in cigarette smokers performing a working memory task: effect of smoking abstinence. Biol Psychiatry 2005;58:143-150
66. Schubert MH, Young KA, Hicks PB. Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol Psychiatry 2006 Sep;60(6):530-533
67. Smith RC, Warner-Cohen J, Matute M, et al. Effects of nicotine nasal spray on cognitive function in schizophrenia. Neuropsychopharmacology 2006;31:637-643
68. George TP, Vessicchio JC, Termine A, et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry 2002;52:53-61
69. Weiner E, Ball MP, Summerfelt A, et al. Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia. Am J Psychiatry 2001;158:635-637
70. Barrickman LL, Perry PJ, Allen AJ, et al. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995 May;34(5):649-657
71. Conners CK, Casat CD, Gualtieri CT, et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 1996 Oct;35(10):1314-1321
72. Wilens TE, Prince JB, Spencer T, et al. An open trial of bupropion for the treatment of adults with attention-deficit/hyperactivity disorder and bipolar disorder. Biol Psychiatry 2003;54:9-16
73. Wilens TE, Spencer TJ, Biederman J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 2001;158:282-288
74. Heatherton TF, Kozlowski LT, Frecker RC, et al. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991;86(9):1119-1127
75. Barr RS, Culhane MA, Jubelt LE, et al. The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology 2008;33:480-490
76. Buchanan RW, Summerfelt A, Tek C, et al. An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr Res 2003;59:29-33
77. Howard AK, Thornton AE, Altman S, et al. Donepezil for memory dysfunction in schizophrenia. J Psychopharmacol 2002;16:267-270
78. Risch SC, McGurk S, Horner MD, et al. A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates. Neurocase 2001;7:105-110
79. Buchanan RW, Conley RR, Dickinson D, et al. Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry 2008;165:82-89
80. Freudenreich O, Herz L, Deckersbach T, et al. Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology (Berl) 2005 Sep;181(2):358-363
81. Tugal O, Yazici KM, Anil Yagcioglu AE, et al. A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int J Neuropsychopharmacol 2004;7:117-123
82. Keefe RS, Malhotra AK, Meltzer HY, et al. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 2008;33:1217-1228
83. Dyer MA, Freudenreich O, Culhane MA, et al. High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. Schizophr Res 2008;33:480-490